CX-4945 oral formulation ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
331特発性多中心性キャッスルマン病1

331. 特発性多中心性キャッスルマン病


臨床試験数 : 33 薬物数 : 41 - (DrugBank : 21) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 123
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00891280
(ClinicalTrials.gov)
February 200929/4/2009Dose-escalation Study of Oral CX-4945A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple MyelomaAdvanced Solid Tumors;Breast Cancer;Inflammatory Breast Cancer;Castleman's Disease;Multiple MyelomaDrug: CX-4945 oral formulationCylene PharmaceuticalsNULLRecruiting18 YearsN/ABoth55Phase 1United States